Is Eltrombopag/Eltrombopag covered by medical insurance? Will you be reimbursed?

Eltrombopag is a thrombopoietin receptor agonist mainly used to treat various types of thrombocytopenia. Its indications include persistent or chronic immune thrombocytopenia (ITP) , thrombocytopenia caused by chronic hepatitis C, and severe aplastic anemia. For patients with ITP, eltrombopag can effectively stimulate platelet production in the bone marrow and help restore patients' platelet levels, thereby reducing the risk of bleeding and improving quality of life. In addition, in patients with chronic hepatitis C, eltrombopag can also effectively increase platelet levels and help patients better tolerate antiviral treatment.

In the Chinese market, the original drug of eltrombopag has been launched, and the specifications include 14 tablets of 25mg and 28 tablets of 25mg. The price is roughly between 2,000 and 4,000 yuan, which reflects the economic burden of the drug to a certain extent. It is worth noting that eltrombopag has been included in the Class B medical insurance project, but the reimbursement policy has certain restrictions. When applying for reimbursement, patients must meet specific indication requirements. Only when these conditions are met can they enjoy medical insurance reimbursement benefits. Therefore, for patients who are not eligible, they need to bear the cost of their medications, which may cause some financial pressure for some patients.

In actual use, patients should undergo regular blood monitoring when receiving eltrombopag treatment to ensure the effectiveness and safety of the drug, and to promptly detect potential side effects, such as abnormal liver function or risk of thrombosis. At the same time, patients should also maintain close communication with their doctors and adjust their medication regimen in a timely manner based on their health status and treatment response.

Reference materials:https://go.drugbank.com/drugs/DB06210